Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation (Q34299035)

1 August 2017

1 reference

title

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation (English)

1 reference

1 August 2017

1 reference

1 reference

W E Delaney

1

1 reference

1 August 2017

S Locarnini

series ordinal

2

1 reference

1 August 2017

T Shaw

series ordinal

3

1 reference

1 August 2017

publication date

1 January 2001

1 reference

Antiviral Chemistry & Chemotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

1-35

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mammalian deoxyribonucleoside kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Clinical Experience with Famciclovir against Hepatitis B Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Reconstructing the complex evolutionary history of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Recombination between sequences of hepatitis B virus from different genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Virus dynamics and drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Baculovirus-mediated gene transfer into mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

An attempt to unify the structure of polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Role of Additional Mutations outside the YMDD Motif of Hepatitis B Virus Polymerase in l(−)SddC (3TC) Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Long-term mutation rates in the hepatitis B virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Structure of the RNA-dependent RNA polymerase of poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Efficient gene transfer into human hepatocytes by baculovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Quantitative Assessment of Hepatitis B Virus DNA during a 24-Week Course of Lamivudine Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Eukaryotic DNA polymerases, a growing family

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus X protein inhibits nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Valine of the YVDD motif of moloney murine leukemia virus reverse transcriptase: role in the fidelity of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A cell culture assay for compounds which inhibit hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B infection: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Chronic hepatitis B virus infection: treatment strategies for the next millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Lamivudine therapy of WHV-infected woodchucks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus X protein: structure, function and biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Novel molecular approaches toward therapy of chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus replication: novel roles for virus-host interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus replication--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vivo study of the mechanism of action of antiviral agents against hepadna virus replication in the liver. Resistance of supercoiled viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The dynamics of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The woodchuck: an animal model for hepatitis B virus infection in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Combination chemotherapy for hepatitis B virus: the path forward?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Combination chemotherapy for hepatitis B virus: the final solution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Preclinical aspects of lamivudine and famciclovir against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Antiviral guanosine analogs as substrates for deoxyguanosine kinase: implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Stereochemical control of DNA biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

DNA polymerases: structural diversity and common mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Physiological concentrations of purines and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

An in vitro system for screening anti-hepatitis B virus drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Anti-human immunodeficiency virus drug combination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

A plethora of lesion-replicating DNA polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Postliver Transplant Allograft Reinfection with a Lamivudine‐Resistant Strain of Hepatitis B Virus: Long Term Follow‐up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Dynamics of hepatitis B virus infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Mutation rate of the hepadnavirus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/095632020101200101

10.1177/095632020101200101

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference